1-3 of 3
Signe Spetalen
Close
Sort by
Journal Articles

Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma

Ivana Spasevska, Ankush Sharma, Chloé B. Steen, Sarah E. Josefsson, Yngvild N. Blaker, Arne Kolstad, Even H. Rustad, Saskia Meyer, Kathrine Isaksen, Stalin Chellappa, Kushi Kushekhar, Klaus Beiske, Mette S. Førsund, Signe Spetalen, Harald Holte, Bjørn Østenstad, Marianne Brodtkorb, Eva Kimby, Johanna Olweus, Kjetil Taskén, Aaron M. Newman, Susanne Lorenz, Erlend B. Smeland, Ash A. Alizadeh, Kanutte Huse, June H. Myklebust
Journal: Blood Advances
Blood Adv (2023) 7 (23): 7216–7230.
https://doi.org/10.1182/bloodadvances.2023010158
Published: 2023
Includes: Supplemental data
Journal Articles

Phase 1/2a study of 177 Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Arne Kolstad, Tim Illidge, Nils Bolstad, Signe Spetalen, Ulf Madsbu, Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, Noelle O'Rourke, Matthew Beasley, Wojciech Jurczak, Unn-Merete Fagerli, Michal Kaščák, Mike Bayne, Aleš Obr, Jostein Dahle, Lisa Rojkjaer, Veronique Pascal, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4091–4101.
https://doi.org/10.1182/bloodadvances.2020002583
Published: 2020
Includes: Supplemental data
Journal Articles

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Clinical Trials & Observations
Sirpa Leppä, Judit Jørgensen, Anne Tierens, Leo Meriranta, Ingunn Østlie, Peter de Nully Brown, Unn-Merete Fagerli, Thomas Stauffer Larsen, Susanna Mannisto, Lars Munksgaard, Martin Maisenhölder, Kaija Vasala, Peter Meyer, Mats Jerkeman, Magnus Björkholm, Øystein Fluge, Sirkku Jyrkkiö, Knut Liestøl, Elisabeth Ralfkiaer, Signe Spetalen, Klaus Beiske, Marja-Liisa Karjalainen-Lindsberg, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1906–1915.
https://doi.org/10.1182/bloodadvances.2020001518
Published: 2020
Includes: Supplemental data